Polynoma LLC

TransCode Therapeutics Acquires Polynoma in $25 Million Deal to Advance Phase 3-Ready Melanoma Vaccine

- TransCode Therapeutics acquired Polynoma LLC from CK Life Sciences in a strategic transaction valued at approximately $165 million on a fully diluted basis, with CK Life Sciences obtaining approximately 91% ownership. - The acquisition brings seviprotimut-L, a novel polyvalent shed antigen vaccine for stage IIB and IIC melanoma that has been safely administered in over 1,000 patients and is Phase 3-ready. - CK Life Sciences concurrently invested $25 million to advance TransCode's lead microRNA therapeutic TTX-MC138 into Phase 2 clinical trials, targeting microRNA-10b as a master regulator of metastatic cancer. - The combined pipeline creates potential synergies between seviprotimut-L's melanoma focus and TTX-MC138's micrometastases targeting capabilities in the same patient population.